Remove tag access-clinical-trials
article thumbnail

Benefits of blockchain in limiting counterfeit drug distribution

European Pharmaceutical Review

A benefit of blockchain in the pharmaceutical supply chain is its compatibility with other technologies such as radio frequency identification (RFID) and barcodes, plus its accessibility throughout the supply chain in real time. Blockchain offers the possibility of non-modifiable data uploading with traceability and low-cost data storage.

92
article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 Pause in UK access.

115
115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.

Cerner 109
article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

article thumbnail

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

The company’s chief executive Michel Vounatsos said he was “obviously disappointed” with the result, which he maintained resulted mainly from a lack of clarity on reimbursement which has delayed patient access. Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug.

Insurance 112
article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” — Dr. Patrizia Cavazzoni (@FDACDERDirector) June 7, 2021.

FDA 98
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. There is currently a rich and diverse IO pipeline that aims to address these unmet needs, with 703 IO products currently in clinical trials. Cost-related unmet needs also scored highly.